干细胞治疗可减少 COPD 慢性支气管炎患者但不减少 COPD 肺气肿患者的 T 细胞凋亡。
Stem cell treatment reduces T cell apoptosis in COPD patients with chronic bronchitis but not with emphysema.
机构信息
Pulmonary and Critical Care, Faculty of Medicine, Marmara University, Turkey.
Department of Immunology, Faculty of Medicine, Marmara University, Turkey; Department of Pediatric Allergy-Immunology, Faculty of Medicine, Marmara University, Turkey.
出版信息
Tissue Cell. 2024 Aug;89:102452. doi: 10.1016/j.tice.2024.102452. Epub 2024 Jun 26.
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a prevalent and preventable condition. Mesenchymal stem cell (MSC) therapy is being explored to aid in the regeneration of lung cells and airway structure, aiming to restore lung function.
AIM
To examine varied responses of MSCs when cultured with peripheral blood mononuclear cells (PBMCs) from different COPD phenotypes, patients were grouped into ACOS, emphysema, and chronic bronchitis categories.
METHODS
PBMCs from these groups and controls were co-cultured with MSCs derived from dental follicles, revealing differing rates of apoptosis among COPD phenotypes compared to controls.
RESULTS
While the chronic bronchitis group exhibited the least lymphocyte viability (p<0.01), introducing MSCs notably enhanced viability across all phenotypes except emphysema, with the chronic bronchitis group showing the most improvement (p<0.05).
CONCLUSION
Stem cell therapy might reduce peripheral lymphocyte apoptosis in COPD, with varying responses based on phenotype, necessitating further research to understand mechanisms and optimize tailored therapies for each COPD subtype.
背景
慢性阻塞性肺疾病（COPD）是一种普遍且可预防的疾病。间充质干细胞（MSC）疗法正在被探索用于辅助肺细胞和气道结构的再生，旨在恢复肺功能。
目的
研究当与来自不同 COPD 表型的外周血单个核细胞（PBMC）共培养时，MSC 的不同反应，将患者分为 ACOS、肺气肿和慢性支气管炎组。
方法
将这些组和对照组的 PBMC 与来源于齿槽骨的 MSC 共培养，结果显示与对照组相比，COPD 表型之间存在不同的细胞凋亡率。
结果
虽然慢性支气管炎组的淋巴细胞活力最低（p<0.01），但引入 MSC 显著提高了所有表型的活力，除了肺气肿组，其中慢性支气管炎组的改善最为显著（p<0.05）。
结论
干细胞疗法可能减少 COPD 外周淋巴细胞的凋亡，基于表型的反应不同，需要进一步研究以了解机制，并为每个 COPD 亚型优化定制治疗。
Zotero 插件